(Q35816396)

10 August 2017

1 reference

title

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance (English)

1 reference

10 August 2017

1 reference

1 reference

1

Hochhaus A

1 reference

10 August 2017

La Rosée P

2

1 reference

10 August 2017

1 August 2004

1 reference

10 August 2017

1 reference

10 August 2017

18

1 reference

10 August 2017

1321-1331

1 reference

10 August 2017

8

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403426

10 August 2017

0 references

cites work

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Lessons learned from the development of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

ARG tyrosine kinase activity is inhibited by STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Cytogenetic and molecular mechanisms of resistance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Resistance to imatinib (Glivec): update on clinical mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Chronic myeloid leukemia-still a few questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell-based measure of Bcr/Abl kinase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Roots of clinical resistance to STI-571 cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Mechanisms and implications of imatinib resistance mutations in BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Imatinib mesylate noncompliance simulating chronic myeloid leukemia resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Specific targeted therapy of chronic myelogenous leukemia with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Imatinib in Philadelphia chromosome-positive chronic phase CML patients: molecular and cytogenetic response rates and prediction of clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Imatinib and beyond--the new CML study IV. A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Position paper on imatinib mesylate in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Emergence of Ph negative clones in chronic myeloid leukemia (CML) patients in complete cytogenetic remission after therapy with imatinib mesylate (STI).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Novel chromosomal aberrations in Philadelphia negative cells of chronic myelogenous leukemia patients on imatinib: report of three cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Simultaneous occurrence of a t(9;22) (Ph) with a t(2;11) in a patient with CML and emergence of a new clone with the t(2;11) alone after imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Imatinib mesylate in combination with other chemotherapeutic drugs: in vitro studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Transplantation for chronic myelogenous leukemia: yes, no, maybe so. . . An Oregon perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Minimal residual disease in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Detection and quantification of residual disease in chronic myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

21 January 2018

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403426

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.LEU.2403426

1 reference

10 August 2017

1 reference

PubMed ID

15215876